COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Sivaloganathan, Helena, Ladikou, Eleni E and Chevassut, Timothy (2020) COVID-19 mortality in patients on anticoagulants and antiplatelet agents. British Journal of Haematology. ISSN 0007-1048

[img] PDF (COVID-19 and antithrombotic drugs) - Accepted Version
Restricted to SRO admin only

Download (398kB)


Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D-dimer and fibrinogen levels (Al-Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang, et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID-19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID-19 (Klok, et al 2020, Stoneham, et al). The term “diffuse pulmonary intravascular coagulopathy” has been proposed to describe the lung-restricted vascular immunopathology associated with COVID-19. This is distinct from disseminated intravascular coagulation in its early stages and is characterised by increased D-dimer with normal platelet count and normal/elevated fibrinogen (McGonagle, et al 2020). Increased VTE rate has been associated with higher D-dimer level, and in the same study, an association between VTE and death was found (Middeldorp, et al 2020). Another study has shown a D-dimer greater than 1 μg/mL was associated with a poorer prognosis (Zhou, et al 2020). Patients requiring mechanical ventilation who were treated with therapeutic anticoagulation had an in-hospital mortality of 29.1% compared to 62.7% in patients who did not receive anticoagulation. Longer duration of anticoagulation was associated with a reduced risk of mortality (Paranjpe, et al 2020).

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: R Medicine
R Medicine > RB Pathology
R Medicine > RM Therapeutics. Pharmacology
Depositing User: Timothy Chevassut
Date Deposited: 10 Jul 2020 10:34
Last Modified: 23 Feb 2022 11:53

View download statistics for this item

📧 Request an update
Project NameSussex Project NumberFunderFunder Ref
Drug-induced selective lethality in populations of DNMT3A knockdown cellsG2782WELLCOME TRUST218435/Z/19/Z
How does SARS CoV-2 infect blood vessels?G3146UK RESEARCH AND INNOVATIONMR/V036750/1
In vitro modelling and therapeutic targeting of tumour cell migration in chronic lymphocytic leukaemia.G2544BLOODWISEUnset
Mining the Wnt signalling-responsive surfaceome for drug targets in acute myeloid leukaemiaG3090WELLCOME TRUSTUnset
Modelling and targeting Acute Myeloid Leukaemia cells in the Bone Marrow protective nicheG3106SUSSEX CANCER FUND FOR TREATMENT AND RESEARCHUnset